glp 1 market GLP-1 Drugs Size to Hit USD 132.79 Bn by 2035 North America Glucagon-Like Peptide-1 (GLP-1)

Opportunities Outside of Diabetes and Obesity Additional Indications for Exploration Additional Indications for Exploration As new companies look to enter the incretin mimetic space, and existing players seek to expand their portfolios, its increasingly important to look beyond diabetes and obesity

Independent testing of gray-market performance and research compounds has repeatedly found under-dosing, over-dosing, wrong actives, and contaminants

Anti-interleukin-17a and anti-Interleukin-23 antibodies may be effective against Alzheimer's disease: role of neutrophils in the pathogenesis

I dont see why one would take the path of a proper drug approval if there is now this less rigorous, alternative path to market, he said